0001209191-23-004871.txt : 20230125 0001209191-23-004871.hdr.sgml : 20230125 20230125175027 ACCESSION NUMBER: 0001209191-23-004871 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230123 FILED AS OF DATE: 20230125 DATE AS OF CHANGE: 20230125 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Donegan Michael C CENTRAL INDEX KEY: 0001627810 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-00100 FILM NUMBER: 23553383 MAIL ADDRESS: STREET 1: 6800 BROKEN SOUND PARKWAY NW STREET 2: THIRD FLOOR CITY: BOCA RATON STATE: FL ZIP: 33487-3507 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: TherapeuticsMD, Inc. CENTRAL INDEX KEY: 0000025743 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870233535 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 951 YAMATO ROAD, SUITE 220 CITY: BOCA RATON STATE: FL ZIP: 33431 BUSINESS PHONE: 561-961-1900 MAIL ADDRESS: STREET 1: 951 YAMATO ROAD, SUITE 220 CITY: BOCA RATON STATE: FL ZIP: 33431 FORMER COMPANY: FORMER CONFORMED NAME: AMHN, Inc. DATE OF NAME CHANGE: 20090930 FORMER COMPANY: FORMER CONFORMED NAME: CROFF ENTERPRISES INC DATE OF NAME CHANGE: 19970915 FORMER COMPANY: FORMER CONFORMED NAME: CROFF OIL CO DATE OF NAME CHANGE: 19920703 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-01-23 0 0000025743 TherapeuticsMD, Inc. TXMD 0001627810 Donegan Michael C 951 YAMATO ROAD SUITE 220 BOCA RATON FL 33431 0 1 0 0 Prin. Fin. and Acctg. Officer Common Stock 2023-01-23 4 M 0 380 0.00 A 4934 D Common Stock 2023-01-23 4 M 0 1066 0.00 A 6000 D Common Stock 2023-01-23 4 M 0 519 0.00 A 6519 D Common Stock 2023-01-23 4 M 0 2400 0.00 A 8919 D Common Stock 2023-01-23 4 S 0 1302 5.3383 D 7617 D Common Stock 2023-01-24 4 S 0 7 5.3101 D 7610 D Restricted Stock Units 0.00 2023-01-23 4 M 0 380 0.00 D Common Stock 380 0 D Restricted Stock Units 0.00 2023-01-23 4 M 0 1066 0.00 D Common Stock 1066 0 D Restricted Stock Units 0.00 2023-01-23 4 M 0 519 0.00 D Common Stock 519 0 D Restricted Stock Units 0.00 2023-01-23 4 M 0 2400 0.00 D Common Stock 2400 0 D Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 23, 2023, the reporting person received 4,365 shares of issuer common stock in settlement of restricted stock units (RSUs). The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices of ranging from $5.32 through $5.37, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth. The RSUs were to vest in three equal installments annually beginning March 30, 2021 and becoming fully vested on March 30, 2023. Vesting was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause". The RSUs were to vest in three equal installments annually beginning July 1, 2022 and becoming fully vested on July 1, 2024. Vesting was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause". Subject to the reporting person's continuous service, the RSUs were to vest in three equal installments annually, beginning September 29, 2022 and becoming fully vested on September 29, 2024. Vesting was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause". The RSUs were to vest in three equal installments annually beginning March 23, 2023 and becoming fully vested on March 23, 2025. Vesting was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause". /s/ Michael C. Donegan 2023-01-25